RD140Beyond's analysis on RD1402026-09-25 — IASO Bio's first-in-human Phase 1 data for the dual-targeted BCMA/GPRC5D CAR-T RD140 could redefine treatment for high-risk multiple myeloma, building on a pipeline that already includes FDA-cleared in vivo CAR-T assetsRecent news mentioning RD1402026-09-25 — 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-TAppears alongsideIMSIASOFasTBrowse the full archive →